aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Average Rating of “Hold” from Brokerages

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have received an average rating of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $25.6667.

Several research analysts have issued reports on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of aTyr Pharma in a report on Friday, March 6th. Wall Street Zen raised aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Sunday.

Institutional Investors Weigh In On aTyr Pharma

Several institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC bought a new stake in shares of aTyr Pharma in the first quarter worth approximately $32,000. Virtu Financial LLC bought a new stake in shares of aTyr Pharma in the fourth quarter worth approximately $62,000. ADAR1 Capital Management LLC grew its stake in shares of aTyr Pharma by 35.9% in the fourth quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock worth $40,000 after acquiring an additional 13,385 shares during the period. AQR Capital Management LLC bought a new stake in shares of aTyr Pharma in the fourth quarter worth approximately $603,000. Finally, Deutsche Bank AG grew its stake in shares of aTyr Pharma by 3,779.5% in the fourth quarter. Deutsche Bank AG now owns 120,341 shares of the company’s stock worth $94,000 after acquiring an additional 117,239 shares during the period. 61.72% of the stock is owned by hedge funds and other institutional investors.

aTyr Pharma Stock Performance

Shares of aTyr Pharma stock opened at $0.52 on Thursday. The stock has a market capitalization of $50.94 million, a PE ratio of -0.71 and a beta of 0.66. aTyr Pharma has a 52-week low of $0.40 and a 52-week high of $7.29. The company has a 50-day simple moving average of $0.80 and a two-hundred day simple moving average of $0.80.

aTyr Pharma (NASDAQ:ATYR) last issued its earnings results on Friday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.05. As a group, equities research analysts forecast that aTyr Pharma will post -0.69 EPS for the current fiscal year.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.